Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) (BRAVIO)
Snakebite, Envenoming, Snake

About this trial
This is an interventional treatment trial for Snakebite focused on measuring Envenoming, Snakebite, varespladib, antidote, snake
Eligibility Criteria
INCLUSION CRITERIA: Is a male or female ≥ 18 years of age with venomous snakebite. Patients must have known or suspected venomous snakebite. In India, enrollment will be restricted to patients bitten by suspected or confirmed Russell's viper (Daboia russelii) or krait (Bungarus spp.) In the U.S., any snakebite that meets all other criteria may be eligible. Participants must meet one of two categories of inclusion criteria: Category 1: The participant is enrolled within 5 hours of venomous snakebite or symptom onset with an SSS score of ≥2 in one system and ≥1 in another system (2+1). OR Category 2: The participant has a suspected or confirmed bite from an elapid and is enrolled within 10 hours of bite or symptom onset with moderate to severe cranial nerve or skeletal muscle weakness. Is willing (or legally authorized representative is willing) to provide informed consent prior to initiation of any study procedures. EXCLUSION CRITERIA: Has history of or is suspected to have CVA or intracranial bleeding of any kind, acute coronary syndrome, MI, or severe pulmonary hypertension. Has known history of inherited bleeding or coagulation disorder. Is, at Screening Visit, using the following anticoagulants: warfarin/coumadin, argatroban, bilvalirudin, lepirudin, apixaban, dabigatran, clopidogrel, prasugrel, ticlodipine or another anticoagulant agent not specifically listed, or has used heparin, enoxaparin, fondaparinux, or other low molecular weight heparin or any antiarrhythmic drugs within 14 days prior to treatment. Has a history of chronic liver disease such as chronic active viral hepatitis, alcohol- related liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis. Reports or has known pre-existing renal impairment or chronic kidney disease. Has a known allergy or significant adverse reaction to varespladib or varespladib-methyl. Is considered by the Investigator to be unable to comply with protocol requirements due to geographic considerations, psychiatric disorders, or other compliance concerns. Is pregnant, has a positive serum human chorionic gonadotropin (hCG) pregnancy test or not willing to use a highly effective method of contraception for 14 days after initial treatment, or is breast-feeding.
Sites / Locations
- Banner University Medical Center - Phoenix
- Arizona Poison & Drug Information CenterRecruiting
- Loma Linda University Medical Center
- Desert Regional Medical CenterRecruiting
- Antelope Valley Medical CenterRecruiting
- University of South Florida/Tampa General Hospital
- Emergency Medicine, University of KentuckyRecruiting
- Duke University Medical CenterRecruiting
- Texas Tech University Health Sciences Center El Paso
- UT Health San Antonio
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC
Placebo Intravenous (IV) + Placebo Oral + SOC
Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.